Michael Francis Doucet, M D in Opelousas, LA - Medicare Dermatology

Michael Francis Doucet, M D is a medicare enrolled "Dermatology" physician in Opelousas, Louisiana. He went to Louisiana State University School Of Medicine In Shreveport and graduated in 1983 and has 41 years of diverse experience with area of expertise as Dermatology. His current practice location is 611 Prudhomme Lane, Suite 6, Opelousas, Louisiana. You can reach out to his office (for appointments etc.) via phone at (337) 948-6366.

Michael Francis Doucet is licensed to practice in Louisiana (license number 017131) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1861565756.

Contact Information

	Michael Francis Doucet, M D
	611 Prudhomme Lane, Suite 6, Opelousas, LA 70570
	(337) 948-6366
	(337) 942-3611

Physician's Profile

Full Name	Michael Francis Doucet
Gender	Male
Speciality	Dermatology
Experience	41 Years
Location	611 Prudhomme Lane, Opelousas, Louisiana
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Michael Francis Doucet attended and graduated from Louisiana State University School Of Medicine In Shreveport in 1983

NPI Data:

NPI Number: 1861565756
Provider Enumeration Date: 11/16/2006
Last Update Date: 07/08/2007

Medicare PECOS Information:

PECOS PAC ID: 5294911491
Enrollment ID: I20110524000799

Medical Identifiers

Medical identifiers for Michael Francis Doucet such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1861565756	NPI	-	NPPES
134860	Medicaid	LA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207N00000X	Dermatology	017131 (Louisiana)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Opelousas General Health System	Opelousas, LA	Hospital
St Martin Hospital	Breaux bridge, LA	Hospital
Mercy Regional Medical Center	Ville platte, LA	Hospital

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Michael Francis Doucet is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Michael Francis Doucet, M D 611 Prudhomme Lane, Suite 6, Opelousas, LA 70570 Ph: (337) 948-6366	Michael Francis Doucet, M D 611 Prudhomme Lane, Suite 6, Opelousas, LA 70570 Ph: (337) 948-6366

News Archive

Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis

Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.

Statins for the prevention of dementia

An increasing number of studies show that elevated serum cholesterol levels might be part of the cause of Alzheimer's disease, but a new review of studies says that, even so, the most successful class of cholesterol-lowering medicines will not stave off the condition.

FDA nod for hepatitis C drug

Merck & Co have finally won the Food and Drugs Administration – FDA'S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.

3SBio files APX001 IND application with SFDA in China

Apexigen, Inc., an emerging biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics, announced today that its partner, 3SBio [SSRX] of Shenyang, China, filed an Investigational New Drug (IND) application for APX001, also known as SSS07, with the State Food and Drug Administration (SFDA) in China.

Study: Green tea extract with polyethylene glycol could help control body weight gain

Evidence has shown that green tea extract may be an effective herbal remedy useful for weight control and helping to regulate glucose in type 2 diabetes.

Michael Francis Doucet, M D - Medicare Dermatology in Opelousas, LA